Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Wilmington R&D Site To Focus On Central Nervous System Drugs

Executive Summary

AstraZeneca's Wilmington, Del. research and development site will focus on developing central nervous system drugs in the restructuring following the merger.

You may also be interested in...



Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.

The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.

Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.

The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.

AstraZeneca Emphasizes Size As Key To Growth In Rx Market

AstraZeneca is guiding investors in the pharmaceutical industry to consider size - both in terms of corporate resources and individual products - as the key to growth.

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel